<DOC>
	<DOCNO>NCT00457535</DOCNO>
	<brief_summary>Responsiveness recombinant human erythropoietin ( rHuEPO ) know related body fatness hemodialysis ( HD ) patient . Adiponectin ( ADPN ) inversely associate body fat mass , healthy subject , low ADPN predictor mortality . Recently , high rHuEPO dose demonstrate associated poor prognosis . So , study , prospectively examine relationship rHuEPO dose , serum ADPN , mortality patient begin HD .</brief_summary>
	<brief_title>Study Relationship Between rHuEPO Dose , Serum ADPN , Mortality Patients Beginning HD</brief_title>
	<detailed_description>We select 85 patient ( 51 men/34 woman , age ; 64±15 year ) survive 3 month start HD . After determine initial rHuEPO dosage , follow patient 3 year , examine association rHuEPO dose , serum ADPN , all-cause mortality . We could follow totally 74 85 patient 3 year ; 59 patient survive , 15 patient expire . Dosage rHuEPO significantly negatively correlate body mass index ( BMI ) ( r=-0.44 , p &lt; 0.01 ) positively serum ADPN ( r=0.29 , p &lt; 0.02 ) , leptin . Cox-hazards regression analysis adjust age , sex underlie kidney disease reveal rHuEPO dose serum ADPN , well nutritional parameter protein catabolic rate become significant determinant 3-year mortality . There 12.7 % risk increase 10U/kg/week increase rHuEPO dose 1.3 % increase 1µg/ml increment serum ADPN 3-year follow-up .</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>patient first start hemodialysis therapy August 2000 May 2001 11 dialysis center Shizuoka prefecture area . nothing particular</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>recombinant human erythropoietin</keyword>
	<keyword>adiponectin</keyword>
	<keyword>mortality</keyword>
</DOC>